Sarepta Therapeutics (SRPT) Debt Ratio (2010 - 2026)
Sarepta Therapeutics' quarterly Debt Ratio came in at 0.26 in Q1 2026, down 19.73% year-on-year from 0.33 in Q1 2025, and up 6.54% quarter-over-quarter from 0.25 in Q4 2025.
Sarepta Therapeutics has reported Debt Ratio for 17 years, with the latest figure at 0.26 in Q1 2026.
- For the quarter ending Q1 2026, Debt Ratio fell 19.73% year-over-year to 0.26; the trailing twelve-month figure through Mar 2026 stood at 0.26 (down 19.73% YoY), and the FY2025 full-year result was 0.25, down 13.75% from the prior year.
- Debt Ratio for Q1 2026 stood at 0.26, up from 0.25 in the prior quarter.
- The five-year high for Debt Ratio was 0.49 in Q4 2022, with the low at 0.25 in Q4 2025.
- Average Debt Ratio over 5 years is 0.36, with a median of 0.36 recorded in 2022.
- Year-over-year, Debt Ratio soared 41.67% in 2022 and dropped 24.34% in 2024.
- Tracing SRPT's Debt Ratio over 5 years: stood at 0.49 in 2022, then declined by 23.18% to 0.38 in 2023, then dropped by 24.34% to 0.29 in 2024, then declined by 13.75% to 0.25 in 2025, then grew by 6.54% to 0.26 in 2026.
- The last three Debt Ratio figures came in at 0.26 (Q1 2026), 0.25 (Q4 2025), and 0.31 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | 0.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.26 |
| Dec 31, 2025 | 0.25 |
| Sep 30, 2025 | 0.31 |
| Jun 30, 2025 | 0.31 |
| Mar 31, 2025 | 0.33 |
| Dec 31, 2024 | 0.29 |
| Sep 30, 2024 | 0.34 |
| Jun 30, 2024 | 0.36 |
| Mar 31, 2024 | 0.38 |
| Dec 31, 2023 | 0.38 |
| Sep 30, 2023 | 0.40 |
| Jun 30, 2023 | 0.40 |
| Mar 31, 2023 | 0.40 |
| Dec 31, 2022 | 0.49 |
| Sep 30, 2022 | 0.49 |
| Jun 30, 2022 | 0.37 |
| Mar 31, 2022 | 0.36 |
| Dec 31, 2021 | 0.35 |
| Sep 30, 2021 | 0.41 |
| Jun 30, 2021 | 0.40 |
| Mar 31, 2021 | 0.39 |
| Dec 31, 2020 | 0.33 |
| Sep 30, 2020 | 0.25 |
| Jun 30, 2020 | 0.24 |
| Mar 31, 2020 | 0.23 |
| Dec 31, 2019 | 0.37 |
| Sep 30, 2019 | 0.26 |
| Jun 30, 2019 | 0.25 |
| Mar 31, 2019 | 0.22 |
| Dec 31, 2018 | 0.26 |
| Sep 30, 2018 | 0.35 |
| Jun 30, 2018 | 0.35 |
| Mar 31, 2018 | 0.33 |
| Dec 31, 2017 | 0.33 |
| Sep 30, 2017 | 0.04 |
| Jun 30, 2017 | 0.02 |
| Mar 31, 2017 | 0.03 |
| Dec 31, 2016 | 0.04 |
| Sep 30, 2016 | 0.04 |
| Jun 30, 2016 | 0.10 |
| Mar 31, 2016 | 0.10 |
| Dec 31, 2015 | 0.08 |
| Sep 30, 2015 | 0.11 |
| Jun 30, 2015 | 0.09 |
| Mar 31, 2015 | 0.01 |
| Dec 31, 2014 | 0.01 |
| Sep 30, 2014 | 0.01 |
| Jun 30, 2014 | 0.00 |
| Mar 31, 2014 | 0.01 |
| Dec 31, 2013 | 0.04 |
| Sep 30, 2013 | 0.12 |
| Jun 30, 2013 | 0.01 |
| Mar 31, 2013 | 0.01 |
| Dec 31, 2012 | 0.01 |
| Mar 31, 2012 | 0.04 |
| Dec 31, 2011 | 0.03 |
| Sep 30, 2011 | 0.03 |
| Jun 30, 2011 | 0.03 |
| Dec 31, 2010 | 0.04 |